Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Commentary
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

In a conversation with CancerNetwork® at the 2024 Annual Oncology Clinical Practice and Research Summit, Andrew M. Evens, DO, MBA, MSc, spoke about a session he moderated at the meeting, in which he and other panelists highlighted ongoing efforts to improve the quality of care for cancer survivors at his institution.

Evens is the deputy director for Clinical Services at Rutgers Cancer Institute and the system director of Medical Oncology and the oncology lead at RWJBarnabas Health Medical Group. He is also the associate vice chancellor for Clinical Innovation and Data Analytics at Rutgers Biomedical and Health Sciences.

Evens contextualized the presentation by describing various gaps in care for survivors of cancer, particularly among adolescent and young adult populations or those who become “lost in transition” as they switch from pediatric to adulthood survivorship. He emphasized a growing effort to mitigate the risks of post-acute or late effects following prior anti-cancer therapy, which can include cardiac disease, lung disease, or increased infections associated with chemotherapy or radiation.

As part of elevating the level of care for cancer survivors, Evens described the collaborative efforts across different departments at his institution, including medical, surgical, and radiation oncologists; pharmacists; nurses; pathologists; and members of the clinical research team. Other international research projects, including those formed in association with the National Cancer Institute, aim to elucidate the granularity of treatment-related toxicity, which may help inform better survivorship care strategies.

“Survivorship includes many factors,” Evens said. “There are physical and emotional factors, and we want to do everything we can as a comprehensive cancer program, and to do what’s best for the patient in a holistic manner. [Beyond the] cancer, it also means the emotional factors and health behavior modifications. For the rest of their life, [we want to] help the patient in every way possible so they can live the most fruitful life. A high quality of life is what we strive for.”

Reference

Evens A, Cole P, Ligresti L, Manne S. Cancer survivorship: scale, scope, and partnerships for patient-centered care. Presented at the 2024 Annual Oncology Clinical Practice and Research Summit; November 15-16, 2024; New Brunswick, NJ.

Recent Videos
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content